Neurotoxicity of antibodies in cancer therapy: A review

Erika Horta, Connie Bongiorno, Mustapha Ezzeddine, Elizabeth C. Neil

Research output: Contribution to journalReview article

Abstract

The objective of this manuscript is to identify the neurological side effect profile associated with different classes of antibodies used in cancer pharmacotherapy and to estimate the frequency in which these neurotoxicity occurs. A systematic review of the literature was conducted using OVID MEDLINE and EMBASE databases for articles written between January of 2010 till August of 2018. The spectrum of neurotoxicity was searched using expanded terminology, medical subject headings, truncation, spelling variations and database specific controlled vocabulary. 2134 citations were retrieved that were narrowed down to 151 when SORT 1 or SORT 2 critical appraisal tool was applied to articles with human subjects. Meta-analysis using random effect model was done to estimate the prevalence of neurological symptoms per class of antibody described in SORT1 and SORT2 articles. It was found that the most common neurotoxicity per antibody class are as follows; Bi-specific T-cell engagers was headache 38% [35–40%; I2 0%]; anti-CD20, neuropathy, 16% [7–24%, I2 65%]; anti-CD30, neuropathy 57% [46–68%, I2 72%]; anti-CD52, neuropathy 5–15%; anti-CTL4, headache 12% [7–16%, I2 49%]; anti-EGFR, headache 25% [11–38%, I2 92%]; anti-Her2, neuropathy 33% [18–49%, I2 98%]; anti-PD1 and PDL1, headache 3% [2–5%, I2 85%]; and anti-VEGF, headache 25% [16–35%, I2 73%]. Therefore, all classes of antibodies used in cancer pharmacotherapy have associated neurotoxicity with a wide spectrum of effects afflicting the nervous system as a whole. The specific side effects and the frequency at which they occur differ per class of antibody. Broader and more severe symptoms were noted to effect patients with preexisting brain lesions.

Original languageEnglish (US)
Article number105566
JournalClinical Neurology and Neurosurgery
Volume188
DOIs
StatePublished - Jan 2020

Fingerprint

Immunoglobulin Isotypes
Headache
Antibodies
Neoplasms
Medical Subject Headings
Controlled Vocabulary
Databases
Therapeutics
Drug Therapy
Terminology
MEDLINE
Nervous System
Vascular Endothelial Growth Factor A
Meta-Analysis
T-Lymphocytes
Brain

Keywords

  • Antibody
  • Cancer
  • Neurotoxicity
  • Pharmacotherapy

PubMed: MeSH publication types

  • Journal Article
  • Review

Cite this

Neurotoxicity of antibodies in cancer therapy : A review. / Horta, Erika; Bongiorno, Connie; Ezzeddine, Mustapha; Neil, Elizabeth C.

In: Clinical Neurology and Neurosurgery, Vol. 188, 105566, 01.2020.

Research output: Contribution to journalReview article

Horta, Erika ; Bongiorno, Connie ; Ezzeddine, Mustapha ; Neil, Elizabeth C. / Neurotoxicity of antibodies in cancer therapy : A review. In: Clinical Neurology and Neurosurgery. 2020 ; Vol. 188.
@article{6cbbe3ab73364a0394e0f2ccf8ac675b,
title = "Neurotoxicity of antibodies in cancer therapy: A review",
abstract = "The objective of this manuscript is to identify the neurological side effect profile associated with different classes of antibodies used in cancer pharmacotherapy and to estimate the frequency in which these neurotoxicity occurs. A systematic review of the literature was conducted using OVID MEDLINE and EMBASE databases for articles written between January of 2010 till August of 2018. The spectrum of neurotoxicity was searched using expanded terminology, medical subject headings, truncation, spelling variations and database specific controlled vocabulary. 2134 citations were retrieved that were narrowed down to 151 when SORT 1 or SORT 2 critical appraisal tool was applied to articles with human subjects. Meta-analysis using random effect model was done to estimate the prevalence of neurological symptoms per class of antibody described in SORT1 and SORT2 articles. It was found that the most common neurotoxicity per antibody class are as follows; Bi-specific T-cell engagers was headache 38{\%} [35–40{\%}; I2 0{\%}]; anti-CD20, neuropathy, 16{\%} [7–24{\%}, I2 65{\%}]; anti-CD30, neuropathy 57{\%} [46–68{\%}, I2 72{\%}]; anti-CD52, neuropathy 5–15{\%}; anti-CTL4, headache 12{\%} [7–16{\%}, I2 49{\%}]; anti-EGFR, headache 25{\%} [11–38{\%}, I2 92{\%}]; anti-Her2, neuropathy 33{\%} [18–49{\%}, I2 98{\%}]; anti-PD1 and PDL1, headache 3{\%} [2–5{\%}, I2 85{\%}]; and anti-VEGF, headache 25{\%} [16–35{\%}, I2 73{\%}]. Therefore, all classes of antibodies used in cancer pharmacotherapy have associated neurotoxicity with a wide spectrum of effects afflicting the nervous system as a whole. The specific side effects and the frequency at which they occur differ per class of antibody. Broader and more severe symptoms were noted to effect patients with preexisting brain lesions.",
keywords = "Antibody, Cancer, Neurotoxicity, Pharmacotherapy",
author = "Erika Horta and Connie Bongiorno and Mustapha Ezzeddine and Neil, {Elizabeth C.}",
year = "2020",
month = "1",
doi = "10.1016/j.clineuro.2019.105566",
language = "English (US)",
volume = "188",
journal = "Clinical Neurology and Neurosurgery",
issn = "0303-8467",
publisher = "Elsevier",

}

TY - JOUR

T1 - Neurotoxicity of antibodies in cancer therapy

T2 - A review

AU - Horta, Erika

AU - Bongiorno, Connie

AU - Ezzeddine, Mustapha

AU - Neil, Elizabeth C.

PY - 2020/1

Y1 - 2020/1

N2 - The objective of this manuscript is to identify the neurological side effect profile associated with different classes of antibodies used in cancer pharmacotherapy and to estimate the frequency in which these neurotoxicity occurs. A systematic review of the literature was conducted using OVID MEDLINE and EMBASE databases for articles written between January of 2010 till August of 2018. The spectrum of neurotoxicity was searched using expanded terminology, medical subject headings, truncation, spelling variations and database specific controlled vocabulary. 2134 citations were retrieved that were narrowed down to 151 when SORT 1 or SORT 2 critical appraisal tool was applied to articles with human subjects. Meta-analysis using random effect model was done to estimate the prevalence of neurological symptoms per class of antibody described in SORT1 and SORT2 articles. It was found that the most common neurotoxicity per antibody class are as follows; Bi-specific T-cell engagers was headache 38% [35–40%; I2 0%]; anti-CD20, neuropathy, 16% [7–24%, I2 65%]; anti-CD30, neuropathy 57% [46–68%, I2 72%]; anti-CD52, neuropathy 5–15%; anti-CTL4, headache 12% [7–16%, I2 49%]; anti-EGFR, headache 25% [11–38%, I2 92%]; anti-Her2, neuropathy 33% [18–49%, I2 98%]; anti-PD1 and PDL1, headache 3% [2–5%, I2 85%]; and anti-VEGF, headache 25% [16–35%, I2 73%]. Therefore, all classes of antibodies used in cancer pharmacotherapy have associated neurotoxicity with a wide spectrum of effects afflicting the nervous system as a whole. The specific side effects and the frequency at which they occur differ per class of antibody. Broader and more severe symptoms were noted to effect patients with preexisting brain lesions.

AB - The objective of this manuscript is to identify the neurological side effect profile associated with different classes of antibodies used in cancer pharmacotherapy and to estimate the frequency in which these neurotoxicity occurs. A systematic review of the literature was conducted using OVID MEDLINE and EMBASE databases for articles written between January of 2010 till August of 2018. The spectrum of neurotoxicity was searched using expanded terminology, medical subject headings, truncation, spelling variations and database specific controlled vocabulary. 2134 citations were retrieved that were narrowed down to 151 when SORT 1 or SORT 2 critical appraisal tool was applied to articles with human subjects. Meta-analysis using random effect model was done to estimate the prevalence of neurological symptoms per class of antibody described in SORT1 and SORT2 articles. It was found that the most common neurotoxicity per antibody class are as follows; Bi-specific T-cell engagers was headache 38% [35–40%; I2 0%]; anti-CD20, neuropathy, 16% [7–24%, I2 65%]; anti-CD30, neuropathy 57% [46–68%, I2 72%]; anti-CD52, neuropathy 5–15%; anti-CTL4, headache 12% [7–16%, I2 49%]; anti-EGFR, headache 25% [11–38%, I2 92%]; anti-Her2, neuropathy 33% [18–49%, I2 98%]; anti-PD1 and PDL1, headache 3% [2–5%, I2 85%]; and anti-VEGF, headache 25% [16–35%, I2 73%]. Therefore, all classes of antibodies used in cancer pharmacotherapy have associated neurotoxicity with a wide spectrum of effects afflicting the nervous system as a whole. The specific side effects and the frequency at which they occur differ per class of antibody. Broader and more severe symptoms were noted to effect patients with preexisting brain lesions.

KW - Antibody

KW - Cancer

KW - Neurotoxicity

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=85074797283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074797283&partnerID=8YFLogxK

U2 - 10.1016/j.clineuro.2019.105566

DO - 10.1016/j.clineuro.2019.105566

M3 - Review article

C2 - 31731087

AN - SCOPUS:85074797283

VL - 188

JO - Clinical Neurology and Neurosurgery

JF - Clinical Neurology and Neurosurgery

SN - 0303-8467

M1 - 105566

ER -